BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32677340)

  • 1. B3GNT5 is a novel marker correlated with stem-like phenotype and poor clinical outcome in human gliomas.
    Jeong HY; Park SY; Kim HJ; Moon S; Lee S; Lee SH; Kim SH
    CNS Neurosci Ther; 2020 Nov; 26(11):1147-1154. PubMed ID: 32677340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of RFX4 is associated with tumor progression and poor prognosis in patients with glioblastoma.
    Jeong HY; Kim HJ; Kim CE; Lee S; Choi MC; Kim SH
    Int J Neurosci; 2021 Jan; 131(1):7-14. PubMed ID: 32075484
    [No Abstract]   [Full Text] [Related]  

  • 3. Growth factor independence underpins a paroxysmal, aggressive Wnt5a
    Trivieri N; Visioli A; Mencarelli G; Cariglia MG; Marongiu L; Pracella R; Giani F; Soriano AA; Barile C; Cajola L; Copetti M; Palumbo O; Legnani F; DiMeco F; Gorgoglione L; Vescovi AL; Binda E
    J Exp Clin Cancer Res; 2022 Apr; 41(1):139. PubMed ID: 35414102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stemness Marker Detection in the Periphery of Glioblastoma and Ability of Glioblastoma to Generate Glioma Stem Cells: Clinical Correlations.
    Raysi Dehcordi S; Ricci A; Di Vitantonio H; De Paulis D; Luzzi S; Palumbo P; Cinque B; Tempesta D; Coletti G; Cipolloni G; Cifone MG; Galzio R
    World Neurosurg; 2017 Sep; 105():895-905. PubMed ID: 28559081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIF1α regulates single differentiated glioma cell dedifferentiation to stem-like cell phenotypes with high tumorigenic potential under hypoxia.
    Wang P; Lan C; Xiong S; Zhao X; Shan Y; Hu R; Wan W; Yu S; Liao B; Li G; Wang J; Zou D; Chen B; Feng H; Wu N
    Oncotarget; 2017 Apr; 8(17):28074-28092. PubMed ID: 28427209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.
    Binder ZA; Siu IM; Eberhart CG; Ap Rhys C; Bai RY; Staedtke V; Zhang H; Smoll NR; Piantadosi S; Piccirillo SG; Dimeco F; Weingart JD; Vescovi A; Olivi A; Riggins GJ; Gallia GL
    PLoS One; 2013; 8(10):e75945. PubMed ID: 24146797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting A20 decreases glioma stem cell survival and tumor growth.
    Hjelmeland AB; Wu Q; Wickman S; Eyler C; Heddleston J; Shi Q; Lathia JD; Macswords J; Lee J; McLendon RE; Rich JN
    PLoS Biol; 2010 Feb; 8(2):e1000319. PubMed ID: 20186265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (lncRNA) NEAT1.
    Lulli V; Buccarelli M; Ilari R; Castellani G; De Dominicis C; Di Giamberardino A; D Alessandris QG; Giannetti S; Martini M; Stumpo V; Boe A; De Luca G; Biffoni M; Marziali G; Pallini R; Ricci-Vitiani L
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32443824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
    Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
    Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PTPRZ1-MET/STAT3/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization.
    Wang Y; Suo J; Wang Z; Ran K; Tian Y; Han W; Liu Y; Peng X
    Cell Signal; 2024 Aug; 120():111191. PubMed ID: 38685521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1/PI3K/AKT signaling.
    Hou Y; Sun B; Liu W; Yu B; Shi Q; Luo F; Bai Y; Feng H
    Theranostics; 2021; 11(2):555-566. PubMed ID: 33391492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDH5 is specifically activated in glioblastoma stemlike cells and contributes to vasculogenic mimicry induced by hypoxia.
    Mao XG; Xue XY; Wang L; Zhang X; Yan M; Tu YY; Lin W; Jiang XF; Ren HG; Zhang W; Song SJ
    Neuro Oncol; 2013 Jul; 15(7):865-79. PubMed ID: 23645533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of ADAMTS3 Suppresses Stemness and Tumorigenicity in Glioma Stem Cell.
    Kim HJ; Jeong HY; Batara DC; Moon C; Lee S; Lee SJ; Park SI; Choi MC; Kim SH
    CNS Neurosci Ther; 2023 Feb; 29(2):682-690. PubMed ID: 36514188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
    Mala U; Baral TK; Somasundaram K
    BMC Cancer; 2022 Jun; 22(1):642. PubMed ID: 35690717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QKI deficiency maintains glioma stem cell stemness by activating the SHH/GLI1 signaling pathway.
    Han B; Wang R; Chen Y; Meng X; Wu P; Li Z; Duan C; Li Q; Li Y; Zhao S; Jiang C; Cai J
    Cell Oncol (Dordr); 2019 Dec; 42(6):801-813. PubMed ID: 31292920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelin-forming cell-specific cadherin-19 is a marker for minimally infiltrative glioblastoma stem-like cells.
    Zorniak M; Clark PA; Kuo JS
    J Neurosurg; 2015 Jan; 122(1):69-77. PubMed ID: 25361488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
    Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
    Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.